Kymera Therapeutics reported collaboration revenue of $99.4 million for the nine months ended September 30, 2026, a significant increase from $36.3 million in the prior year. Despite this, the company recorded a net loss of $262.4$ million for the period due to rising research and development expenses, which reached $346.2 million.
Kymera Therapeutics reported financial results for the third quarter ended September 30, 2026, and announced positive Phase 1 data for its IRF5 degrader, KT-579. The company remains well-capitalized with $1.6 billion in cash, providing a runway into 2029, and expects topline Phase 2b data for its STAT6 degrader, KT-621, by year-end 2026.
Term
Q3 2026
“Kymera’s recent progress reinforces the opportunity across our portfolio and our ability to help shape a new era of differentiated oral medicines in immunology. With KT-621 and KT-579, we are advancing complementary immunoregulatory mechanisms that target distinct drivers of disease, with significant potential to address unmet needs across the current treatment landscape.”
Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics
“The positive results from the Phase 1 healthy volunteer trial of KT-579, which we reported today, demonstrate strong translation of its preclinical pharmacology into humans and highlight its potential to modulate multiple core inflammatory pathways through a single oral mechanism.”
Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics